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Retinoic Acid (RA) signaling is mediated by the Retinoic Acid Receptor (RAR), belonging to the Nuclear Hormone Receptor superfamily. In addition to its classical 
transcriptional actions, RAR also mediates rapid transcription-independent actions (also called non-genomic), consisting in the activation of signal transduction 
pathways, as the phosphatidyl-inositol-3-kinase (PI3K) or the ERK MAP-kinase signaling pathways. RA-induced rapid actions play roles in different physiological 
contexts. As an effort towards understanding the functions of those rapid actions on signaling elicited by RA, we have identified nuclear proteins whose phosphorylation 
state is rapidly modified by RA treatment in neuroblastoma cells, using a proteomic approach. Our results show that RA treatment led to changes in the phosphorylation 
patterns in two families of proteins: (i) those related to chromatin dynamics in relation to transcriptional activation, and (ii) those related to mRNA processing and in 
particular mRNA splicing. We show that treatment of neuroblastoma cells with RA leads to alteration of the regulation of pre-mRNA splicing and mRNA translation, via the 
activation of signaling pathways. Thus, our results underscore novel functions for the non-genomic signaling elicited by RAR in the regulation of mRNA processing, as 
part of a cellular response orchestrated by the nuclear receptor RAR. The results shown here contribute to the idea that transcriptional and transcription-independent 
actions elicited by nuclear hormone receptors are integrated and converge at multiple levels in the regulation of gene expression.  
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1. Short RA treatments lead to modifications in 
the phosphorylation patterns of nuclear proteins 
Short RA treatments induce the activation of the PI3K 
signalling pathway and its downstream components 
mTOR and p70S6 Kinase (Fig. 1A). Western blot with an 
antibody against phospho-serine/threonine residues 
within Akt kinase phosphorylation consensus site 
(RXRXXS/T), revealed that RA treatment increased 
rapidly the phosphorylation of several Akt substrate 
proteins, detectable in whole cell extracts (Fig. 1B), as 
well as in nuclear extract (Fig. 1C). 2-DE western blots 
demonstrate that RA treatment leads to an increase in 
the number and intensity of the spots corresponding to 
phosphorylated Akt substrates in nuclear extracts from 
neuroblastoma cells (Fig. 1D). 
 
 
2. A proteomic approach to the identification of RA-
induced phosphorylation changes in nuclear proteins 
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7. RA treatment modifies the alternative splicing 
pattern on endogenous genes in neuroblastoma cells 
Preliminary data obtained with 
Affymetrix Human Gene 1.0ST 
microarray, which uses exon-
specific probes, indicate that RA-
induced changes in the alternative 
splicing pattern take place in a 
significant number of genes. The 
figure shows examples of RA-
induced exon-inclusion as well as 
a complex pattern including both 
exon inclusion and skipping 
induced by RA 
We provide the first evidence 
that RA, through the activation 
of signalling pathways, could 
regulate mRNA splicing and 
translation.  
The results shown here 
contribute to the idea that 
transcriptional and 
transcription-independent 
actions elicited by nuclear 
hormone receptors are 
integrated and converge at 
multiple levels in the regulation 
of gene expression.   
8. Conclusions 
6. RA regulates translation through the activation of 
signaling pathways 
By using a translation reporter gene 
containing a binding site for SF2/ASF (Fig. 
6A) we show RA-induced increase in 
translation, that was sensitive to 
inhibitors of both PI3K and ERK-MAP 
kinase pathways (Fig.6B). 
RA increases the phosphorylation of 4E-
BP1, an inhibitor of cap-binding eIF4E, 
through the activation of PI3K (Fig. 6C). 
However additional mechanisms must 
exist to explain the effects of MEK 
inhibitor  U0126, that does not interferes 
the activation of PI3K pathway (Fig. 6D).  
Using a splicing reporter minigene based 
on E1A (Fig. 5A) we could show that RA 
treatment alters the pattern of alternative 
splicing. This regulation is sensitive to 
PI3K inhibitors, but not to MAP kinase 
inhibitors. (Figs. 5B and C).  
The interaction betweenthe SR protein 
SF2/ASF and the U1-70K spliceosome 
protein is increased by RA treatment, as 
shown in immunoprecipitation 
experiments (Fig. 5D) 
5. RA influences the regulation of alternative splicing 
via activation of signaling pathways 
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Nuclear phospho-proteins from cells treated for 30 min with RA 
or  vehicle were prepared by affinity chromatography. The two 
samples were electrophoresed in 2D-gels and the patterns of 
spots compared. Differentially phosphorylated proteins were 
isolated and identified by Mass Spectrometry. RA-induced 
phosphorylation was validated in 2D-western blot.  
4. iTRAQ: GeneOntology analysis of RA-induced 
differentially phosphorylated proteins 
 
 
Among the proteins whose 
phosphorylation is modified by RA, the 
proteins involved in RNA metabolism are 
majority. The percentage of proteins 
involved in mRNA splicing is remarkable. 
Therefore we have postulated the following 
 
 
 
HYPOTHESIS: 
RA, trough the rapid activation of signaling pathways could 
regulate mRNA processing/splicing as part of a cellular 
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3. Analysis of RA-induced differentially 
phosphorylated proteins trough the iTRAQ assay 
The iTRAQ method is based in the labeling of 
peptide fractions with reporter tags of 
different masses. We run in parallel the 
affinity-purified nuclear phospho-proteins 
from cells treated during 0, 15 and 30 min with 
RA. After denaturation and trypsin digestion, 
the samples were labeled and mixed The 
peptides were separated by multi-dimensional 
nano-liquid chromatography, and thedifferent 
fractions analyzed by tandem Mass Spec. The 
proteins are identified on the basis of peptide 
fragments, and a relative quantification is 
obtained from the relative levels of each  
reporter tag. 
The iTRAQ assay resulted in the 
identification of 63 proteins whose 
phosphorylation changed as effect of RA 
treatment.  
